ストックスクリーナーアプリを入手
8.23
0.12%
-0.010
Grifols Sa Adr (GRFS) 最新ニュース
Mittleman Value Partners 2025 Year-End & Q1 2026 Investment Review - Seeking Alpha
Grifols (NASDAQ: GRFS) 2025 revenue rises as leverage and risk factors stay elevated - Stock Titan
CapEx per share of Grifols, S.A. Sponsored ADR Class B – LSX:A1J1E2 - TradingView
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors - AD HOC NEWS
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates - GlobeNewswire Inc.
Grifols S.A. Stock: Navigating Debt Reduction Through US Biopharma IPO Plans Amid Market Pressures - AD HOC NEWS
Grifols S.A. stock surges as board approves potential US IPO for biopharma unit, unlocking value in - AD HOC NEWS
The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026 - FinancialContent
Grifols SA stock surges as board greenlights potential US IPO of plasma unit to slash debt and fuel - AD HOC NEWS
Grifols S.A. stock surges on board approval for potential US IPO of biopharma unit - AD HOC NEWS
Grifols: I'm Very Happy To Add In 2026 (NASDAQ:GRFS) - Seeking Alpha
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag By Investing.com - Investing.com India
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag - Investing.com
Earnings call transcript: Grifols Q4 2025 sees robust growth in IG franchise - Investing.com Canada
Grifols SA (GRFS) (Full Year 2025) Earnings Call Highlights: Strong Revenue Growth Amidst ... By GuruFocus - Investing.com Canada
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
Contrasting Grifols (NASDAQ:GRFS) & Sigyn Therapeutics (OTCMKTS:SIGY) - Defense World
Airbus SE – Unsponsored ADR (OTCMKTS:EADSY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Grifols S.A. the Most Slept-On Biotech Play Right Now? - AD HOC NEWS
Revenue per share of Grifols, S.A. Sponsored ADR Class A – MUN:G0F - TradingView — Track All Markets
Grifols: Positive/Neutral Scenario Posits An Upside (NASDAQ:GRFS) - Seeking Alpha
European Index Open Up Ahead of Crucial Data Prints -- Market Talk - 富途牛牛
Price to book ratio of Grifols, S.A. Sponsored ADR Class B – BOATS:GRFS - TradingView
Validea's Top Health Care Stocks Based On Martin Zweig11/12/2025 - Nasdaq
Grifols ADR earnings matched, revenue fell short of estimates By Investing.com - Investing.com UK
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
6 undervalued stocks with low beta - Morningstar Australia
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Spanish court opens investigation into Gotham City's attack on Grifols - Reuters
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Europe Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper - Reuters
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again - GlobeNewswire
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire
Grifols stock falls amid potential Moody's downgrade, new short report - Seeking Alpha
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar Canada
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF - Macau Business
San Gabriel Valley Tribune - FinancialContent
Cramer 'Takes A Pass' On Stock That's Down 31% Over Past 6 Months: 'Don't Want To Go Against Musk' - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Grifols S.A. Investigated by Block & Leviton For Potential - GlobeNewswire
Which Trades Are Top Funds Making? - Morningstar Canada
Shares at Spain's Grifols rise on cost-cutting plan - Reuters
Grifols SA (GRFS) Stock Price, News & Analyst Forecast - eToro
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - Newswire Canada
What is the current Price Target and Forecast for Grifols (GRFS) - Zacks Investment Research
8 Newly Undervalued 5-Star Stocks - Morningstar
Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation - Stock Titan
1.39%
0.62%
大文字化:
|
ボリューム (24 時間):